1112978-84-3

1112978-84-3 structure

Name: Leucettine L41
Chemical Name: leucettine L41
CAS Number: 1112978-84-3
Molecular Formula: C₁₇H₁₃N₃O₃
Molecular Weight: 307.303
Catalog: Signaling Pathways Cell Cycle/DNA Damage CDK
Create Date: 2018-06-23 07:41:37
Modify Date: 2025-08-31 11:12:20
Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), DYRK2, CDC-like kinase 1 (CLK1), and CLK3 (IC50s = 0.04, 0.035, 0.015, and 4.5 µM, respectively)[1]. Leucettine L41 prevents lipid peroxidation and the accumulation of reactive oxygen species (ROS) induced by Aβ25-35 in the hippocampus in a mouse model of Alzheimer’s disease-like toxicity. Leucettine L41 also prevents memory deficits induced by Aβ25-35 in the same model[2].

Name	leucettine L41
Synonyms	(5Z)-2-Anilino-5-(1,3-benzodioxol-5-ylmethylene)-1,5-dihydro-4H-imidazol-4-one leucettine L41 4H-Imidazol-4-one, 5-(1,3-benzodioxol-5-ylmethylene)-3,5-dihydro-2-(phenylamino)-, (5Z)-

Description	Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), DYRK2, CDC-like kinase 1 (CLK1), and CLK3 (IC50s = 0.04, 0.035, 0.015, and 4.5 µM, respectively)[1]. Leucettine L41 prevents lipid peroxidation and the accumulation of reactive oxygen species (ROS) induced by Aβ25-35 in the hippocampus in a mouse model of Alzheimer’s disease-like toxicity. Leucettine L41 also prevents memory deficits induced by Aβ25-35 in the same model[2].
Related Catalog	Signaling Pathways >> Protein Tyrosine Kinase/RTK >> DYRK Signaling Pathways >> Cell Cycle/DNA Damage >> CDK Research Areas >> Neurological Disease
References	[1]. Debdab M, et al. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86. [2]. Naert G, et al. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice. Eur Neuropsychopharmacol. 2015 Nov;25(11):2170-82.